Send to

Choose Destination
Expert Opin Pharmacother. 2003 Sep;4(9):1525-33.

Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost.

Author information

Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1071, USA.

Erratum in

  • Expert Opin Pharmacother. 2003 Oct;4(10):1887.


Psoriasis is a common, unpredictable, chronic immune-mediated disease characterised by skin lesions and frequently associated with arthritis. Although rarely fatal, psoriasis has a tremendous impact on a patients' quality of life. Traditional therapies for severe psoriasis include phototherapy, methotrexate, oral retinoids and cyclosporin. New biological agents add to the treatment options for psoriasis; however, they raise the already considerable cost of managing the disease. In considering efficacy, safety and cost-effectiveness, ultraviolet Type B (UVB) phototherapy appears to be the best first-line agent for the control of psoriasis. Methotrexate, psoralen plus UVA, alefacept, etanercept and infliximab are appropriate second-line agents, the choice of which requires considerable patient input and physician judgement. Developing rational, effective and acceptable strategies to manage psoriasis treatments would encourage cost-effective psoriasis management.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center